Atraric acid
Based on 1 Customer Validation
Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases.
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 4707-47-5
- Formula: C10H12O4
- Molecular Weight:196.20
-
Storage:
RT, stored under nitrogen.
In solvent -80°C, 1 year , -20°C, 6 months
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HaCaT | IC50 |
>5 μM
Compound: 2
|
Antiproliferative activity against human HaCaT cells
Antiproliferative activity against human HaCaT cells
|
[PMID: 10395495] |
| PMNL | IC50 |
>60 μM
Compound: 2
|
Inhibition of LTB4 biosynthesis in A-23187-stimulated bovine PMNL cells
Inhibition of LTB4 biosynthesis in A-23187-stimulated bovine PMNL cells
|
[PMID: 10395494] |
Atraric acid (10 μM; CV1 cells) represses the transactivation function mediated by Dihydrotestosterone-induced human AR[1].
Atraric acid (10 μM; PCa cells) inhibits the expression of the PSA gene in both androgen-dependent and androgen-independent PCa cells[1].
Atraric acid (1-300 μM; 24 h) dose-dependently inhibits pro-inflammatory cytokine, nitric oxide, prostaglandin E2 in LPS-stimulated RAW264.7 cells, but does not influence the cell viability[2].
Atraric acid (100 and 300 μM; 18 h or 4 h) downregulates the expression of phosphorylated IκB, extracellular signal-regulated kinases (ERK) and nuclear factor kappa B (NFκB) signaling pathway to exhibit anti-inflammatory effects in LPS-stimulated RAW264.7 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW264.7 cells
-
Concentration:1-300 μM
-
Incubation Time:24 h
-
Result:Did not influence the cell viability.
-
Cell Line:RAW264.7 cells
-
Concentration:100 and 300 μM
-
Incubation Time:18 h or 4 h
-
Result:Inhibited LPS-Induced expression of iNOS and COX-2 in a dose-dependent manner.
Suppressed LPS-stimulated phosphorylation of the Nfκb signaling pathway.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c mice (7 weeks old, 17-20 g; LPS-induced endotoxin shock)[2]
-
Dosage:10, 30 mg/kg
-
Administration:i.p.; single dosage
-
Result:Inhibited the production of pro-inflammatory cytokines.
Reduced pathological damages such as vasodilation and bleeding.
Chemical Information
-
CAS No. 4707-47-5
-
Appearance Solid
-
Molecular Weight 196.20
-
Formula C10H12O4
-
Color White to off-white
-
SMILES
O=C(OC)C1=C(C)C=C(O)C(C)=C1O
-
Synonyms
Methyl atrarate
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
RT, stored under nitrogen
In solvent -80°C 1 year -20°C 6 months
Solvent & Solubility
DMSO : 100 mg/mL (509.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Papaioannou M, et al. The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth. J Cell Mol Med. 2009 Aug;13(8B):2210-2223. [Content Brief]
[2]. Roell D, Baniahmad A. The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth. Mol Cell Endocrinol. 2011 Jan 30;332(1-2):1-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.0968 mL | 25.4842 mL | 50.9684 mL | 127.4210 mL |
| 5 mM | 1.0194 mL | 5.0968 mL | 10.1937 mL | 25.4842 mL | |
| 10 mM | 0.5097 mL | 2.5484 mL | 5.0968 mL | 12.7421 mL | |
| 15 mM | 0.3398 mL | 1.6989 mL | 3.3979 mL | 8.4947 mL | |
| 20 mM | 0.2548 mL | 1.2742 mL | 2.5484 mL | 6.3711 mL | |
| 25 mM | 0.2039 mL | 1.0194 mL | 2.0387 mL | 5.0968 mL | |
| 30 mM | 0.1699 mL | 0.8495 mL | 1.6989 mL | 4.2474 mL | |
| 40 mM | 0.1274 mL | 0.6371 mL | 1.2742 mL | 3.1855 mL | |
| 50 mM | 0.1019 mL | 0.5097 mL | 1.0194 mL | 2.5484 mL | |
| 60 mM | 0.0849 mL | 0.4247 mL | 0.8495 mL | 2.1237 mL | |
| 80 mM | 0.0637 mL | 0.3186 mL | 0.6371 mL | 1.5928 mL | |
| 100 mM | 0.0510 mL | 0.2548 mL | 0.5097 mL | 1.2742 mL |